Business
Sernova Announces Appointment of Executive Chair to Complement its Management Team
(TheNewswire) LONDON, ON - TheNewswire - December 2 ...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Appointment of Executive Chair to Complement its Management Team\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n LONDON, ON -\n \n \n \n \n TheNewswire -\n \n \n \n \n December 2\n \n \n \n \n , 2021\n \n \n \n \n -\n \n \n \n Sernova Corp\n \n \n .\n \n \n (TSXV:SVA)\n(FSE/XETRA:PSH)(OTC:SEOVF),\n \n \n a leading\nclinical-stage company focused on regenerative medicine therapeutics,\nis pleased to announce that\n \n Frank Holler, member and chairman\nof the Sernova board of directors, will assume a new role of Executive\nChair in order to augment the current leadership team and further\nsupport the Company’s evolving corporate and R&D activities and\nobjectives.\n \n \n “Frank Holler is an experienced veteran in the biotech industry and\nI look forward to leveraging his expertise and experience to build on\nour momentum at the forefront of the regenerative therapeutics\nspace,” said Dr. Philip Toleikis, President & CEO.\n \n \n Mr. Holler added, “With our success to date, the Sernova Board of\nDirectors believes we are at a critical juncture in the Company’s\nmaturation as we manage the growth of our clinical and pre-clinical\nprograms, progress our multiple partnering relationships and leverage\ncapital markets opportunities. With these additional responsibilities,\nI am thrilled to lend executive expertise to our current management\nand look forward to working even more closely with Dr. Philip\nToleikis, and his leadership team to achieve key corporate objectives\nfocused on the creation and realization of additional shareholder\nvalue.”\n \n \n Mr. Holler is presently President & CEO of Ponderosa Capital Inc.\nand has previously held Chair or CEO roles at Lions Capital Corp.,\nXenon Pharmaceuticals, Inc. and ID Biomedical Corporation. He was also\na founding director of Angiotech Pharmaceuticals, Inc. Prior to his\nexperiences in biotechnology and healthcare, Mr. Holler was an\ninvestment banker with Merrill Lynch Canada and Wood Gundy, Inc. (now\nCIBC World Markets).\n \n \n \n ABOUT\n \n \n SERNOVA\n \n \n \n \n Sernova is developing regenerative medicine therapeutic\ntechnologies using an implantable medical device and immune protected\ntherapeutic cells (i.e., human donor cells, corrected human cells and\nstem cell-derived cells) to improve the tr...